… In this study based on a French nationwide cohort of patients with … differ between initiating
a JAKi and initiating adalimumab. … Disease-modifying antirheumatic drugs (DMARDs) inhibit …

… ) or other biological disease modifying antirheumatic drugs (… adalimumab. In addition,
some of the inclusion and exclusion criteria were not possible to emulate due to the register-based …

… tumor necrosis factor inhibitor (TNFi; adalimumab, certolizumab pegol, golimumab, etanercept…
VTEs (defined as deep vein thrombosis [DVT] or pulmonary embolism [PE]) were collected …

… The high and very high CVD risk categories based on SCORE2 … synthetic disease-modifying
anti-rheumatic drugs (… 2/day) to TNF inhibitors (adalimumab in the US, etanercept in the rest …

… with traditional disease-modifying antirheumatic drugs. In … were categorised into three groups
based on the underlying cause… venous thrombosis resistant to these treatments, anti-TNF-α …

… TNF) inhibitor (etanercept or adalimumab) or sulfasalazine and … Based on these, we originally
proposed a recruitment target … Canakinumab Antiinflammatory Thrombosis Outcome Study …

… synthetic disease-modifying antirheumatic drug (csDMARD), … venous thromboembolism. A
black-box warning for the risk of … between JKIs and abatacept, adalimumab, etanercept, and …

… It should be noted, however, that data from TREAT (Therapy, Resource, Evaluation, and …
anti-TNF treatment in CD, showed an increased risk of VTE in patients taking anti-TNF therapy (…

… occurring together constitute venous thromboembolism (VTE)… have suggested that
disease-modifying anti-rheumatic drugs (… the biologic group were matched based on propensity …

… based on exposure to upadacitinib and adalimumab. Efficacy … adverse cardiac events,
venous thromboembolism and deaths. … While biological disease-modifying antirheumatic drugs (…